Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
Objective
The objective is to prospectively study nonischemic cardiomyopathy patients qualified for CRT-D following currently approved standard indications in order to:
- Validate the MADIT-CRT- derived model predicting fast VT/VF in Nonischemic cardiomyopathy patients with QRS>120 ms
- Determine whether CMR added to the risk model validated in specific aim 1 will further improve risk stratification for predicting fast VT/VF in Nonischemic cardiomyopathy patients with QRS>120 ms
- Evaluate costs of risk stratification using Holter and CMR in relationship to costs of implanted devices without risk stratification
Eligibility
- Optimal pharmacologic therapy as defined by published guidelines from the American Heart Association and the American College of Cardiology for at least 3 calendar months after NICM diagnosis
- Nonischemic dilated cardiomyopathy meeting current primary prevention indications for CRT-D:
- QRS ≥ 120 ms for LBBB patients with NYHA class II, III or IV (ambulatory), OR
- QRS ≥ 120 ms for non-LBBB patients with NYHA class III or IV (ambulatory), OR
- QRS ≥ 150 ms for non-LBBB patients with NYHA class II
As evidenced by ECG qualifying patient for CRT-D implant within 12 calendar months prior to consent
- LVEF ≤ 35% within 12 calendar months prior to or on consent date by angiographic, cardiac nuclear test, CMR or echocardiographic methods
- Sinus rhythm by most recent ECG qualifying patient for CRT-D implant
